Last updated: April 24, 2026
Ribociclib Succinate: Who Supplies It and the Upstream Supply Chain
Ribociclib succinate is supplied through a network that typically splits into (1) the licensed API manufacturer(s) that provide ribociclib API and (2) the salt/finished-dose manufacturers that convert API into ribociclib succinate for commercial drug product. In practice, the commercially used ribociclib succinate supply chain is dominated by the originator and its contract manufacturing partners for both API and tablets.
Who supplies ribociclib succinate for commercial use?
For the approved brand regimen, ribociclib succinate is distributed as tablets under the trade name Kisqali (Novartis). The supply chain is tied to Novartis’ commercial manufacturing network and its licensed suppliers for API and finished dosage forms.
Key supplier anchor points used by industry in diligence and sourcing workflows:
| Supply tier |
Supplier role |
Company (typical role in Kisqali chain) |
Evidence signal |
| Finished dose |
Market authorization holder distribution and commercial supply |
Novartis |
Drug labeling and EU/US regulatory dossiers for Kisqali |
| API |
Licensed API manufacturer(s) for ribociclib |
Contract API manufacturers to Novartis supply chain |
Listed in regulatory filings and quality sections for Kisqali |
| Salt form |
Salt conversion of ribociclib to ribociclib succinate |
Salt processing under CMO/QMS within supply chain |
Salt form specified in product labeling and regulatory CMC |
| Distribution |
Wholesale drug distribution |
Commercial distributors |
National drug distribution networks; product availability tied to MAH |
What this means for sourcing: ribociclib succinate is usually not bought as a generic bulk chemical by end users without qualification. Most procurement routes use approved supplier lists, quality agreements, and dossier-linked manufacturing sites.
What exact product form do suppliers deliver?
Ribociclib succinate is supplied as either:
- Bulk drug substance (API): ribociclib in the succinate salt form is generally not marketed as generic “succinate API” to customers; ribociclib is commonly the API form, while the commercial product is the succinate salt.
- Drug product (tablets): Kisqali tablets contain ribociclib (as the succinate salt) and use the succinate form for dosing and stability.
Regulatory product labeling and CMC specify the salt in the drug product composition and the manufacturing route controlled under GMP.
How to identify ribociclib succinate suppliers in practice (regulatory-linked sourcing)
Pharma buyers typically source using one or both of the following evidence channels:
- Regulatory dossiers and quality sections that name the manufacturing sites for:
- drug substance (API) manufacturing
- drug product manufacturing
- testing and release
- Public drug product documentation (labeling, EPAR/US prescribing info) that ties the product to the MAH’s commercial supply chain.
For Kisqali, the key diligence approach is to treat supplier identification as a “site-listing” problem: the supplier is the manufacturer at a named facility, not a trading intermediary.
API and drug product manufacturers: how supplier lists are typically structured
Even when multiple firms participate, the supplier table buyers use for ribociclib succinate generally breaks down into:
| Manufacturing step |
Typical supplier category |
What you get |
| Ribociclib synthesis (API) |
API manufacturer (CMO) |
GMP API or API intermediate material for salt conversion |
| Salt formation |
Salt-form conversion in CMC process |
Ribociclib succinate salt material used in drug product manufacture |
| Formulation and tableting |
Drug product manufacturer |
Kisqali tablets with defined mg strength(s) |
| Release testing |
Quality control lab network |
COA-linked batch release and stability program tie-in |
This is the structure buyers use to negotiate supply terms, qualify quality systems, and ensure dossier alignment.
What supplier information is publicly consistent for ribociclib succinate?
The most stable publicly verifiable facts are:
- Trade product identity: ribociclib succinate is marketed as Kisqali by Novartis.
- Dose form: oral tablets containing ribociclib (succinate).
- Regulatory labeling link: FDA label and EU authorization documentation anchor the commercial manufacturing program to the MAH.
Public supply chain confirmation at the individual supplier-company level often requires dossier review or site-specific regulatory statements.
Key supplier archetypes for ribociclib succinate procurement
Procurement teams typically encounter three supplier archetypes:
- Originator-led supplier chain (Novartis-backed): API and drug product manufacturers operate under Novartis commercial agreements and quality system oversight.
- Specialty chemical/salt and API CMOs (authorized under quality agreements): firms that provide API material, salt formation steps, or both.
- Drug product CMOs (tablet manufacturing and packaging): firms that finish the dosage form under Novartis control.
This supplier architecture is typical for high-value oncology small molecules like ribociclib.
Key Takeaways
- Ribociclib succinate is supplied commercially through the Novartis Kisqali supply chain, which includes qualified API and drug product manufacturing sites.
- For sourcing decisions, the practical supplier identification method is regulatory-linked site listing (drug substance and drug product manufacturing sites), not retail trading networks.
- “Supplier” in diligence typically means the named GMP facility for API/salt formation and the named finished-dose manufacturer, both under the MAH-controlled quality system.
FAQs
1) Who is the main supplier of ribociclib succinate commercially?
Novartis, as the marketing authorization holder for Kisqali (ribociclib succinate tablets).
2) Are ribociclib succinate suppliers the same as API suppliers?
Not necessarily. Commercial supply chains usually split API manufacture and salt conversion/formulation/tableting across different qualified sites.
3) What product form do most regulated suppliers deliver?
They deliver GMP drug product (tablets) or GMP drug substance material used in manufacture. The drug product contains ribociclib (as the succinate salt).
4) How do procurement teams verify ribociclib succinate supplier suitability?
By mapping candidate suppliers to the named GMP manufacturing sites referenced in regulatory quality documentation and through COA/test results tied to that site.
5) Can ribociclib succinate be sourced as a generic salt from any chemical supplier?
In regulated pharma procurement, bulk “generic” sourcing is usually constrained by qualification requirements and dossier alignment; the supplier must meet the relevant GMP and quality agreement expectations tied to the drug product program.
References
[1] Novartis Pharmaceuticals Corporation. Kisqali (ribociclib) tablets prescribing information. FDA label.
[2] European Medicines Agency. Kisqali EPAR (assessment report) and product information.
[3] US FDA. Drug Approval Package and labeling for Kisqali (ribociclib).
